A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis

Yevgeniy Gindin,Chuhan Chung,Zhaoshi Jiang,Jing Zhu Zhou,Jun Xu,Andrew N. Billin,Robert P. Myers,Zachary Goodman,Abdolamir Landi,Michael Houghton,Richard M. Green,Cynthia Levy,Kris V. Kowdley,Christopher L. Bowlus,Andrew J. Muir,Michael Trauner

DOI: https://doi.org/10.1002/hep.31488

IF: 17.298

2021-02-28

Hepatology

Abstract:<p>Primary sclerosing cholangitis (PSC) is a heterogeneous cholangiopathy characterized by progressive biliary fibrosis. RNA sequencing (RNA‐Seq) of liver tissue from PSC patients (n=74) enrolled in a 96‐week clinical trial was performed to identify associations between biological pathways that were independent of fibrosis and clinical events. The effect of fibrosis was subtracted from gene expression using a novel computational approach. The fibrosis‐adjusted gene expression patterns were associated with time to first PSC‐related clinical event (e.g. cholangitis, hepatic decompensation) and differential expression based on risk groups and Ingenuity Pathway Analysis (IPA) were performed. Baseline demographic data were representative of PSC: median age 48 years, 71% male, 49% with IBD, and 44% with bridging fibrosis or cirrhosis. The first principle component (PC1) of RNA‐Seq data accounted for 18% of variance and correlated with fibrosis stage (ρ=‐0.80; P&lt;0.001). After removing the effect of fibrosis‐related genes, PC1 was not associated with fibrosis (ρ=‐0.19; P=0.11) and a semi‐supervised clustering approach identified two distinct patient clusters with differential risk of time to first PSC‐related event (P&lt;0.0001). The two groups had similar fibrosis stage, hepatic collagen content and α‐SMA expression by morphometry, ELF score, and serum liver biochemistry, bile acids, and IL‐8 (all p&gt;0.05). The top pathways identified by IPA were eIF2 signaling and regulation of eIF4/p70S6K signaling. Genes involved in the unfolded protein response (UPR), <i>ATF6 </i> and <i>eIF2 </i>, were differentially expressed between the PSC clusters (down‐regulated in the high‐risk group by log‐fold‐changes of ‐0.18 [P=0.02] and ‐0.16 [P=0.02], respectively). Clinical events were enriched in the high versus low‐risk group (38% [12/32] vs 2.4% [1/42], p&lt;0.0001). Conclusions<b>: </b> Removing the contribution of fibrosis‐related pathways uncovered alterations in the UPR, which were associated with liver‐related complications in PSC.</p>

gastroenterology & hepatology